science_technology_and_other_research_and_development · DOD-AMRAA

DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award

Defense Health Agency Contracting Activity - DHACA · HT942526BCRPTBCCDA

Closed

Total Program Funding

$140K

Expected Awards

Deadline

July 8, 2026

GRANTQUICK SUMMARYPlain-English Overview

DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award. Defense Health Agency Contracting Activity - DHACA. Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a... $140,000 total program funding; ~1 awards expected.

Who Should Apply

Unrestricted (any eligible entity)

Who Should NOT Apply

Few restrictions — most eligible entities can apply

Key Requirements (Plain English)

•Deadline: 2026-07-08

💡 GrantQuick Tip

Clearly demonstrate alignment with funding priorities and provide measurable outcomes.

Competitiveness: Very high — extremely limited awards available

What This Grant Funds

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.

Distinctive Features:

· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.

· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.